• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer
【2h】

Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer

机译：首次诊断为晚期前列腺癌的化疗 - 革命还是进化？来自英国尿液肿瘤学组英国调查的结果，评估肿瘤学家对一线多西紫杉醇联合雄激素剥夺治疗对去势敏感的转移性和高风险/局部晚期前列腺癌的看法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: \ud\udThere have been three randomised trials investigating docetaxel in combination with androgen deprivation therapy as first-line therapy for hormone-sensitive metastatic and locally advanced/high-risk prostate cancer. The largest of these studies, UK STAMPEDE trial, recently presented in June 2015. The aim of this survey was to evaluate if oncologists' practice has changed as a result of these studies, or if their practice is likely to change in different clinical settings in the future.\ud\udMaterials and methods: \ud\udThe British Uro-oncology Group issued a semi-structured online questionnaire to its membership of 160 specialist urological oncologists practising in the UK. Links to the abstracts of GETUG-AFU-15, E3805 CHAARTED and STAMPEDE were attached with the survey for respondents to review before completing the survey.\ud\udResults: \ud\udIn total, 111 participants completed the survey; 87% stated that STAMPEDE will influence their clinical practice in the future. Almost all (96%) would offer docetaxel with androgen deprivation therapy to men presenting with high volume metastatic prostate cancer. Fewer oncologists would offer this treatment to men with low volume metastatic prostate cancer, locally advanced or relapsed disease. Various patient- and disease-related factors were considered in decision making, as well as resource implications.\ud\udConclusions: \ud\udThis survey reports oncologists' attitudes towards a major change in practice in the standard of care for men with newly diagnosed advanced prostate cancer in the UK. The survey highlighted the complexities surrounding the clinical implementation of the data from these studies, including changes in referral pathways, with the early involvement of oncologists in such patients' care, increases in workloads for oncologists and chemotherapy units and the need for national approval for re-imbursement of these treatments.
机译：目的：\ ud \ ud已有三项随机试验研究多西他赛联合雄激素剥夺疗法作为激素敏感性转移性和局部晚期/高危前列腺癌的一线治疗。这些研究中最大的一项是最近于2015年6月提交的UK STAMPEDE试验。该调查的目的是评估这些研究是否改变了肿瘤科医生的执业，或者他们的执业是否可能在不同的临床环境中发生变化。 \ ud \ ud材料和方法：\ ud \ ud英国Uro肿瘤学小组向其在英国执业的160名泌尿外科肿瘤专家组成的成员发布了半结构化在线问卷。随调查附上GETUG-AFU-15，E3805 CHAARTED和STAMPEDE的摘要链接，供受访者在完成调查之前进行审核。\ ud \ ud结果：\ ud \ ud总共有111名参与者完成了调查； 87％的人表示，STAMPEDE将来会影响他们的临床实践。几乎所有（96％）的人都会为患有高转移性前列腺癌的男性提供多西他赛联合雄激素剥夺疗法。较少的肿瘤学家会为患有少量转移性前列腺癌，局部晚期或复发性疾病的男性提供这种治疗。决策过程中考虑了各种与患者和疾病相关的因素，以及对资源的影响。\ ud \ ud结论：\ ud \ ud这项调查报告了肿瘤学家对新诊断男性护理标准实践中重大变化的态度。英国晚期前列腺癌。该调查强调了这些研究数据临床实施的复杂性，包括转诊途径的改变，肿瘤学家对此类患者的早期干预，肿瘤学家和化学治疗部门工作量的增加以及需要获得国家批准以进行重新治疗。 -这些治疗的费用。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号